Clinical experiences using radium-223, a novel α-emitting bone-seeking radiopharmaceutical, in breast and prostate cancer patients with skeletal metastases

被引：0
|
作者：
Nilsson, S
Larsen, RH
Bruland, OS
机构：
[1] Norwegian Radium Hosp, Oslo, Norway
[2] Algeta ASA, Oslo, Norway
[3] Karolinska Hosp, S-10401 Stockholm, Sweden
来源：
CANCER TREATMENT REVIEWS | 2005年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
51
引用
收藏
页码：S30 / S31
页数：2
相关论文
共 50 条
  • [41] Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases
    Wakita, Naoto
    Hara, Takuto
    Suzuki, Kotaro
    Terakawa, Tomoaki
    Teishima, Jun
    Nakano, Yuzo
    Miyake, Hideaki
    ANTICANCER RESEARCH, 2024, 44 (06) : 2627 - 2635
  • [42] The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience
    De Luca, Rossella
    Costa, Renato Patrizio
    Tripoli, Vincenzo
    Murabito, Alessandra
    Cicero, Giuseppe
    ONCOLOGY, 2018, 94 (03) : 161 - 166
  • [43] Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
    Axel Heidenreich
    Silke Gillessen
    Daniel Heinrich
    Daniel Keizman
    Joe M. O’Sullivan
    Joan Carles
    Manfred Wirth
    Kurt Miller
    John Reeves
    Monica Seger
    Sten Nilsson
    Fred Saad
    BMC Cancer, 19
  • [44] Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
    Heidenreich, Axel
    Gillessen, Silke
    Heinrich, Daniel
    Keizman, Daniel
    O'Sullivan, Joe M.
    Carles, Joan
    Wirth, Manfred
    Miller, Kurt
    Reeves, John
    Seger, Monica
    Nilsson, Sten
    Saad, Fred
    BMC CANCER, 2019, 19 (1)
  • [45] Radiographic and laboratory assessment of bone metastases in castration-resistant prostate cancer patients undergoing Radium-223 dichloride therapy
    Takalkar, Amol
    Paryani, Bhavna
    Skweres, Justin
    Adams, Scott
    Devarakonda, Srinivas
    Dhawan, Manish
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [46] Radium-223 dichloride treatment for prostate cancer with bone metastases: A symptomatic outcome review of 12 months experience
    Lee, H. H.
    McAddy, N. C.
    O'Sullivan, P.
    Crawley, P.
    Beesley, S.
    Naji, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S214 - S215
  • [47] Radium-223 dichloride in castration-resistant prostate cancer with symptomatic bone metastases: a guide to its use
    Shirley M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2016, 32 (3) : 98 - 103
  • [48] The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases
    Ram, Prasanna
    Mandal, Swarnendu
    Das, Manoj K.
    Nayak, Prasant
    PROSTATE, 2023, 83 (06): : 613 - 613
  • [49] The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases
    Liu, Alex J.
    Kosiorek, Heidi E.
    Ueberroth, Benjamin E.
    Jaeger, Ellen
    Ledet, Elisa
    Kendi, Ayse T.
    Tzou, Katherine
    Quevedo, Fernando
    Choo, Richard
    Moore, Cassandra N.
    Ho, Thai H.
    Singh, Parminder
    Keole, Sameer R.
    Wong, William W.
    Sartor, Oliver
    Bryce, Alan H.
    PROSTATE, 2022, 82 (12): : 1202 - 1209
  • [50] Initial post-approval clinical experience with Radium-223 dichloride in patients with prostate cancer
    Conti, Peter
    Challa, Sudha
    Jadvar, Hossein
    Pinski, Jacek
    Gross, Mitchell
    Dorff, Tanya
    Quinn, David
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
12345